Ozzion (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Ozzion, is a proton pump inhibitor (PPI) presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Ozzion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ozzion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastroesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive esophagitis: heals damaged esophageal lining caused by chronic acid exposure. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare endocrine tumor. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence risk. - Helicobacter pylori eradication regimens (as adjunct): enhances effectiveness of antibiotic‑based eradication therapy.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Vitamin B12 deficiency with long‑term use: fatigue, neuropathy. - Bone fractures (with prolonged therapy): increased risk of hip, wrist, or spine fractures. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing pantoprazole, clinicians should consider several safety aspects: - Assess renal function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for altered absorption of drugs that need an acidic environment. - Monitor long‑term users: watch for signs of vitamin B12 deficiency, magnesium loss, and bone density changes. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Contraindications: avoid in patients with known hypersensitivity to pantoprazole or other PPIs. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several medicines. Awareness of key interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption and efficacy. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet activity, consider alternative therapy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Methotrexate (high dose): reduced renal clearance, watch for toxicity. - Digoxin: slight increase in serum levels, assess for signs of toxicity. - Oral contraceptives: may lower hormone levels, advise backup contraception.